Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy

PURPOSE: Dinutuximab (Unituxin™; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma. United Therapeutics Corporation (UTC) assumed ch14.18 production from the National Cancer Institute (NCI); this study eval...

Descripción completa

Detalles Bibliográficos
Autores principales: Marachelian, Araz, Desai, Ami, Balis, Frank, Katzenstein, Howard, Qayed, Muna, Armstrong, Michael, Neville, Kathleen A., Cohn, Susan L., Bush, Mark, Gunawan, Rudy, Lim, Allison Pecha, Smith, Malcolm A., Mary Smith, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747995/
https://www.ncbi.nlm.nih.gov/pubmed/26791869
http://dx.doi.org/10.1007/s00280-015-2955-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747995/
https://www.ncbi.nlm.nih.gov/pubmed/26791869
http://dx.doi.org/10.1007/s00280-015-2955-9

Ejemplares similares